Strategic Pharma Collaborations The Fibrolamellar Cancer Foundation has established partnerships with Dialectic Therapeutics, Cancer Research Institute, and Dracenpharma to advance clinical research, indicating a proven approach to sponsor-funded trials and drug supply for rare cancer studies. This presents an opportunity to formalize and scale collaboration models with oncology-focused biotechs and pharma sponsors for early phase trials and patient access programs.

Clinical Trial Recruitment Focusing on teens and young adults with fibrolamellar cancer positions the foundation as a key partner for patient recruitment, trial navigation, and registry development. Offering dedicated recruitment support, digital engagement, and patient registries could attract sponsorship and accelerate enrollment for current and upcoming studies.

Fundraising Platform Modernization With a modest tech stack and revenue in the mid range, the foundation could benefit from upgrading donor management, CRM, and fundraising automation. A modern platform could enhance sponsor reporting, grant management, and multi-channel campaigns to attract corporate sponsors and philanthropic donors.

Data Analytics Partnerships The foundation’s research focus creates an opportunity to partner on data sharing, translational analytics, and patient-reported outcomes. Offering secure data collaboration, analytics services, and standardized data pipelines could demonstrate impact to funders and collaborators while speeding research insights.

Education and Awareness Aligned with the mission to raise awareness and improve communication among clinicians and patients, there is potential for co branded educational programs, clinician training modules, and patient resources. Sponsorship or licensing opportunities around CME content and online education could broaden reach and funding.